The expression of yes-associated protein in ovarian serous adenocarcinoma and clinical significance

doi:10.3877/cma.j.issn.2095-655X.2017.02.013

Abstract

Abstract:

Objective

To investigate the expressive significance of yes-associated protein(YAP) and its relationship with clinical pathological features in ovarian serous Adenocarcinoma (OSAC).

Methods

Forty normal and 120 OSAC patients were enrolled, whose was ovarian tissue were confirmed by pathological examination in the Central Hospital of TaiAn from January 2008 to December 2012.The expression of YAP in 120 cases of OSAC and 40 cases of normal was detected by immunohistochemically Streptavidin-peroxidase(SP) method to analyze its relationship with the clinical pathological features.

Results

The positive rate of YAP was higher in OSAC group (69.2%, 83/120) than that in normal ovarian tissue(7.5%, 3/40) (χ²=45.89, P<0.01). In OSAC, the expression of YAP in low level group (51.1%, 23/45) was significantly different with the high level group (80.0%, 60/75) (χ²=11.01, P<0.01). The expression of YAP in stage Ⅲ and Ⅳ group(86.9%, 20/23) was significantly different from the stage Ⅰand Ⅱgroup(64.9%, 63/97) (χ²=6.44, P<0.01). The expression of YAP in group with lymph node metastasis(88.9%, 24/27) was also significantly different from that in group without lymph node metastasis(63.4%, 59/93) (χ²=6.35, P<0.01).

Conclusions

YAP may participate in the process of occurrence and progression in OSAC.Detection of YAP may be an effective parameter in evaluating occurrence, progression and prognosis of OSAC, and may play an important role in early prediction of OSAC.

Key words: Ovarian neoplasms, Adenocarinoma, Yes-associated protein

Yuanyuan Ban, Wei Zhang, Daosheng Li. The expression of yes-associated protein in ovarian serous adenocarcinoma and clinical significance[J]. Chinese Journal of Diagnostics(Electronic Edition), 2017, 05(02): 128-131.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhzdxdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-655X.2017.02.013

https://zhzdxdzzz.cma-cmc.com.cn/EN/Y2017/V05/I02/128

Figures/Tables 2

References 20

[1]	王海燕,彭李博,王建军, 等. EphA1蛋白在卵巢浆液性腺癌中的表达及其临床意义[J]. 临床肿瘤学杂志, 2014, 19(11): 996-999.
[2]	李道胜,班媛媛. 卵巢伴微浸润的浆液性交界性肿瘤临床病理学特征分析[J/CD]. 中华诊断学电子杂志, 2016, 4(2): 116-119.
[3]	Liu M,Zhao S,Lin Q, et al.YAP regulates the expression of Hoxa1 and Hoxc13 in mouse and human oral and skin epithelial tissues[J]. Mol Cell Biol, 2015, 35(8): 1449-1461.
[4]	Greenspan DL,Connolly DC,Wu R, et al.Loss of FHIT expression in cervical carcinoma cell lines and primary tumors[J]. Cancer Res, 1997, 57(21): 4692-4698.
[5]	Dong J,Feldmann G,Huang J, et al.Elucidation of a universal size-control mechanism in drosophila and mammals[J]. Cell, 2007, 130(6): 1120－1133.
[6]	Lamar JM,Stern P,Liu H, et al.The hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain[J]. Proc Natl Acad Sci U S A, 2012, 109(37): E2441-2450.
[7]	Liu YC,Wang YZ.Role of Yes-associated protein 1 in gliomas：pathologic and therapeutic aspects[J]. Tumour Biol, 2015, 36(4): 2223-2227.
[8]	Cao JJ,Zhao XM,Wang DL, et al.YAP is overexpressed in clear cell renal cell carcinoma and its knockdown reduces cell proliferation and induces cell cycle arrest and apoptosis[J]. Oncol Rep, 2014, 32(4): 1594-1600.
[9]	Zhang L,Yang S,Chen X, et al.The hippo pathway effector, YAP, regulates motility, invasion and castration-resistant growth of prostate cancer cells[J]. Mol Cell Biol, 2015, 35(8): 1350-1362.
[10]	Guo J,Kleeff J,Zhao Y, et al. Yes-associated protein(YAP65) in relation to Smad7 expression in human pancreatic ductal adenocarcinoma[J]. Int J Mol Med, 2006, 17(5): 761-767.
[11]	Steinhardt AA,Gayyed MF,Klein AP, et al. Expression of Yes-associated protein in common solid tumors[J]. Hum Pathol, 2008, 39(11): 1582-1589.
[12]	Zhang X,George J,Deb S, et al. The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene[J]. Oncogene, 2011, 30(25): 2810-2822.
[13]	Muramatsu T,Imoto I,Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma[J]. Carcinogenesis, 2011, 32(3): 389-398.
[14]	Muramatsu T,Imoto I,Matsui T, et al. YAP is a candidate oncogene for esophageal squamous cell carcinoma[J]. Carcinogenesis, 2011, 32(3): 389-398.
[15]	Kim JM,Kang DW,Long LZ, et al. Differential expression of Yes-associated protein is correlated with expression of cell cycle markers and pathologic TNM staging in non-small-cell lung carcinoma[J]. Hum Pathol, 2011, 42(3): 315-323.
[16]	Zhou Z,Zhu JS,Xu ZP.TRNA interference mediated YAP gene silencing inhibits invasion and metastasis of human gastric cancer cell line SGC-7901[J]. Hepatogastroenterology, 2011, 58(112): 2156-2161.
[17]	Tsujiura M,Mazack V,Sudol M, et al.Yes-associated protein (YAP) modulates oncogenic features and radiation sensitivity in endometrial cancer[J]. PLoS One, 2014, 9(6): e100974.
[18]	Hall CA,Wang R,Miao J, et al. Hippo pathway effector Yap is an ovarian cancer oncogene[J]. Cancer Res, 2010, 70(21): 8517-8525.
[19]	He C,Lv X,Hua G, et al.YAP forms autocrine loops with the ERBB pathway to regulate ovarian cancer initiation and progression[J]. Oncogene, 2015, 34(50): 6040-6054.
[20]	Yoshikawa K,Noguchi K,Nakano Y, et al. The Hippo pathway transcriptional co-activator, YAP, confers resistance to cisplatin in human oral squamous cell carcinoma[J]. Int J Oncol, 2015, 46(6): 2364-2370.

组别	总例数	阳性	阴性
卵巢浆液性腺癌组	120	83	37
正常卵巢组织组	40	3	37
χ²值	?	45.89	?
P值	?	0.000	?

组别	总例数	阳性	阴性
卵巢浆液性腺癌组	120	83	37
正常卵巢组织组	40	3	37
χ²值	?	45.89	?
P值	?	0.000	?

Please choose a citation manager

Content to export